Abstract
The formation of R- andS-norfluoxetine was analyzed in vitro in human liver microsomes. Low apparent Km values forR-norfluoxetine formation of ≤8 μM andS-norfluoxetine of <0.2 μM were determined.R-Norfluoxetine formation rates in a characterized microsomal bank correlated with the catalytic activities for cytochrome P450 (CYP) 2D6, CYP2C9, and CYP2C8. Expressed CYP2C9, CYP2C19, and CYP2D6 formed R-norfluoxetine following incubation with 1 μM R-fluoxetine and exhibited apparentKm values of 9.7, 8.5, and 1.8 μM, respectively. Multivariate correlation analysis identified CYP2C9 and CYP2D6 as significant regressors with R-norfluoxetine formation. Antibodies to the CYP2C subfamily and CYP2D6 each exhibited moderate inhibition of R-norfluoxetine formation. Therefore, CYP2D6 and CYP2C9 contribute to this biotransformation. At pharmacological concentrations of S-fluoxetine,S-norfluoxetine formation rates in the bank of microsomes were found to correlate only with CYP2D6 catalytic activity and only expressed CYP2D6 was found to be capable of formingS-norfluoxetine. Thus, it would appear that both CYP2D6 and CYP2C9 contribute to the formation ofR-norfluoxetine, whereas only CYP2D6 is responsible for the conversion to S-norfluoxetine. Since the enantiomers of fluoxetine and norfluoxetine are inhibitors of CYP2D6, upon chronic dosing, the CYP2D6-mediated metabolism of the fluoxetine enantiomers would likely be inhibited, resulting in R-norfluoxetine formation being mediated by CYP2C9 and S-norfluoxetine formation being mediated by multiple high Kmenzymes.
Footnotes
-
Send reprint requests to: Barbara J. Ring, Lilly Corporate Center, Mail Drop 0730, Eli Lilly and Co., Indianapolis, IN 46285. E-mail:ring_barbara_j{at}lilly.com
- Abbreviations:
- CYP
- cytochromes P450
- PM
- poor metabolizer of CYP2D6 substrates
- EM
- extensive metabolizer of CYP2D6 substrates
- HL
- human liver
- FMO
- flavin-containing monooxygenase
- HPLC
- high-performance liquid chromatography
- bql
- below quantifiable limit
- Received September 12, 2000.
- Accepted February 19, 2001.
- The American Society for Pharmacology and Experimental Therapeutics